Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
Bernhard K. Krämer, Sibylle J. Hauske, Robert Chilton, Johannes F.E. Mann, Lars Gullestad, David Fitchett, Michaela Mattheus, Dominik Steubl, Christoph Wanner
Dive into the research topics of 'Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes'. Together they form a unique fingerprint.